A dual role for the class III PI3K, Vps34, in platelet production and thrombus growth

Colin Valet1, Marie Levade1,2, Gaëtan Chicanne1

  • 1Institut des Maladies Métaboliques et Cardiovasculaires, Inserm U1048, Université Toulouse III, Toulouse, France.

Blood
|September 15, 2017
PubMed

Insights

Vps34 is crucial for platelet production and activation. Its deficiency impairs megakaryocyte granule formation and platelet thrombus formation, highlighting a dual role in platelet health and function.

Area of Science:

  • Hematology
  • Cell Biology
  • Molecular Biology

Background:

  • Vps34 is the only class III phosphoinositide 3-kinase (PI3K).
  • Its role in megakaryocytes (MKs) and platelets is not fully understood.
  • Understanding Vps34's function is critical for platelet disorders.

Purpose of the Study:

  • To investigate the function of Vps34 in MKs and platelets.
  • To elucidate Vps34's role in platelet production and activation.
  • To determine Vps34's impact on thrombus formation.

Main Methods:

  • Generated a mouse model with Vps34 deletion in MK/platelet lineage (Pf4-Cre/Vps34lox/lox).
  • Analyzed MK polyploidisation, proplatelet formation, and granule biogenesis.
  • Assessed platelet activation, secretion, and thrombus formation in vitro and in vivo.
  • Utilized Vps34-specific inhibitors (SAR405, VPS34-IN1).

Main Results:

  • Vps34 deletion in MKs led to microthrombocytopenia and abnormal platelet granules.
  • Vps34 deficiency impaired MK granule biogenesis and directional migration.
  • Vps34 loss reduced phosphatidylinositol 3-monophosphate (PI3P) levels, causing trafficking defects.
  • Vps34 inhibition in platelets affected secretion and thrombus growth, indicating a role in activation.
  • Vps34 deficiency reduced in vivo platelet prothrombotic capacity.

Conclusions:

  • Vps34 plays a dual role in regulating platelet production by MKs.
  • Vps34 is an unexpected regulator of platelet activation and arterial thrombus formation.
  • Targeting Vps34 may offer therapeutic strategies for thrombotic disorders.

Related Concept Videos

Structure and Function of Platelets01:18

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
4.0K
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
9.9K
Phosphoinositides and PIPs01:42

Phosphoinositides and PIPs

Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
10.4K
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
9.5K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.4K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.1K